# A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

> **NCT02267863** · PHASE1 · TERMINATED · sponsor: **Aptose Biosciences Inc.** · enrollment: 21 (actual)

## Conditions studied

- Acute Myelogenous Leukemia in Relapse
- Acute Myelogenous Leukemia, Relapsed, Adult
- Acute Myelogenous Leukemia, Adult
- Acute Myelogenous Leukemia
- High Risk Myelodysplasia

## Interventions

- **DRUG:** APTO-253

## Key facts

- **NCT ID:** NCT02267863
- **Lead sponsor:** Aptose Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Drug manufacturing process and procedure review
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267863, "A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02267863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*